Dipeptidyl peptidase IV inhibitors

IDrugs

Volumn 5, Issue 6, 2002, Pages 577-585

  Evans, D Michael ^a  

^a Ferring Research Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,2,3,4 TETRAHYDRO 3 ISOQUINOLINYL)CARBONYL 2 PYRROLIDINECARBONITRILE DERIVATIVE; 1 (2 AMINOACYL) 2 CYANOPYRROLIDIDE DERIVATIVE; 2 CYANO 3,4 DEHYDROPYRROLIDINE DERIVATIVE; 2 CYANOPYRROLIDIDE DERIVATIVE; 3,7 DIHYDROPURINE 2,6 DIONE DERIVATIVE; 4 AMINOCYCLOHEXANE DERIVATIVE; AMINO ACID DERIVATIVE; ANTIDIABETIC AGENT; CARBON; DIHYDROPURINE 2,6 DIONE DERIVATIVE; DIPEPTIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FLUOROOLEFIN DERIVATIVE; GLIBENCLAMIDE; GLUTAMIC ACID DERIVATIVE; HISTIDYLVALYLPROLINE PYRIDINIUM METHYL KETONE; ISOLEUCINE; ISOQUINOLINE DERIVATIVE; LYSINE DERIVATIVE; METFORMIN; ORNITHINE DERIVATIVE; PIOGLITAZONE; PRODRUG; PROLINE DERIVATIVE; PYRROLIDINE DERIVATIVE; ROSIGLITAZONE; SULFOSTIN; THIAZOLIDIDE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; CHIRALITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; IC 50; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0038791462     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W, Lambeir AM, Durinx C, Goosens F, Haemers A: The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem (1999) 6:311-327. Excellent review of DPP-IV and the therapeutic potential for DPP-IV inhibitors.
2. Sedo A, Malik R: Dipeptidyl peptidase IV-like molecules: Homologous proteins or homologous activities? Biochim Biophys Acta (2001) 1550:107-116.
3. Misumi Y, Hayashi Y, Arakawa F, Ikehara Y: Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim Biophys Acta (1992) 1131:333-336.
4. Mentlein R: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept (1999) 85:9-24. Good discussion of the role of DPP-IV.
5. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionone and is responsible for their degradation in human serum. Eur J Biochem (1993) 214:829-835.
6. Von Bonin A, Huhn J, Fleischer B: Dipeptidyl-peptidase IV/CD26 on T-cells: Analysis of an alternative T-cell activation pathway. Immunol Rev (1998) 161:43-53.
7. Morimoto C, Schlossman SF: The structure and function of CD26 in the T-cell immune response. Immunol Rev (1998) 161:55-70.
8. Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D: Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth. Int J Mol Med (1999) 4:3-15.
9. Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF: A guardian angel: The involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci (2000) 99:93-104.
10. Yaron A, Naider F: Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol (1993) 28:31-81.
11. De Meester I, Korom S, Van Damme J, Scharpe S: CD26, let it cut or cut it down. Immunol Today (1999) 20:367-375.
12. Nausch I, Mentlein R, Heymann E: The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol Chem Hoppe Seyler (1990) 371:1113-1118.
13. Holst JJ: Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab (1999) 10:229-235.
14. Drucker DJ: Glucagon-like peptides. Diabetes (1998) 47:159-169.
15. Deacon CF, Hughes TE, Holst JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in anesthetized pig. Diabetes (1998) 47:764-769. Report of action of DPP-IV inhibitors on GLP-1.
16. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47:1253-1258.
17. Holst JJ, Deacon CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes (1998) 47:1663-1670.
18. Heins J, Welker C, Schonlein C, Born I, Hartrodt B, Neubert K, Tsuru D, Barth A: Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. Biochim Biophys Acta (1988) 954:161-169.
19. Rahfeld J, Schutkowski M, Faust J, Neubert K, Barth A, Heins J: Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney. Biol Chem Hoppe Seyler (1991) 372:313-318.
20. Villhauer EB, Coppola GM, Hughes TE: DPP-IV inhibition and therapeutic potential. Ann Rep Med Chem (2001) 36:191-200. Excellent review on DPP-IV inhibitors.
21. Schön E, Born I, Demuth HU, Faust J, Neubert K, Steinmetzer T, Barth A, Ansorge S: Dipeptidyl peptidase IV in the immune system: Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem (1991) 372:305-311.
22. Augustyns K, Laambeir AM, Borloo M, De Meester I, Vedernikova I, Vanhoof G, Hendriks D, Scharpé S, Haemers A: Pyrrolidides: Synthesis and structure-activity relationships as inhibitors dipeptidyl peptidase IV. Eur J Med Chem (1997) 32:301-310.
23. Boduszek B, Oleksyszyn J, Kam CM, Selzer J, Smith RE, Powers JC. Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J Med Chem (1994) 37:3969-3976.
24. aa-boroPro dipeptides. J Med Chem (1996) 39:2087-2094.
25. Ashworth DM, Atrash B, Baker GR, Baxter AJ, Jenkins PD, Jones DM, Szelke M: 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett (1996) 6:1163-1166.
26. Ashworth DM, Atrash B, Baker GR, Baxter AJ, Jenkins PD, Jones DM, Szelke M: 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett (1996) 6:2745-2748.
27. Li J, Wilk E, Wilk S: Aminoacylpyrrolidide-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch Biochem Biophys (1995) 323:148-154.
28. Sudre B, Broqua P, White RB, Ashworth DM, Evans DM, Haigh R, Junien J, Aubert ML: Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes (2002) 51:1461-1469. Report on the use of 2-cyanopyrrolidide derivatives in the prevention of diabetes.
29. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB. NVP-DPP728 (1-[[[2-[(5-cyanopyridinyl-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidin e), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry (1999) 38:11597-11603.
30. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia (1999) 42:1324-1331. Report on the activity of 2-cyanopyrrolidide derivatives in models of diabetes.
31. Yamada M, Okagaki C, Higashijima T, Tanaka S, Ohnuki T, Sugita T: A potent dipeptide inhibitor of dipeptidyl peptidase IV. Bioorg Med Chem Lett (1998) 8: 1537-1540.
32. Nguyen C, Blanco J, Mazaleyrat JP, Krust B, Callebaut C, Jacotot E, Hovanessian AG, Wakselman M: Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26. J Med Chem (1998) 41:2100-2110.
33. Coppola GM, Zhang YL, Schuster HF, Russell ME, Hughes TE: 1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors. Bioorg Med Chem Lett (2000) 10:1555-1558.
34. Lin J, Toscano PJ, Welch JT: Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics. Proc Nat Acad Sci USA (1998) 95:14020-14024.
35. University of Sydney (Abbott CA, Gorell MD): Dipeptidyl peptidases. WO-00119866 (2001).
36. Ferring BV (Qi S, Akinsanya KO, Riviere PJ.-M, Junien J-L): Novel serine protease genes related to DPPIV. WO-00231134 (2002).
37. Ferring BV (Jenkins PD, Jones DM, Szelke M): DP-IV serine protease inhibitors. WO-09515309 (1995). First patent claiming 2-cyanopyrrolidide derivatives as stable and potent inhibitors of DPP-IV.
38. Novartis AG (Villhauer EB): N-substituted 2-cyanopyrrolidines. WNO-09819998 (1998). First patent claiming N-(substituted-glycyl)-cyanopyrrolidide derivatives as stable and potent inhibitors of DPP-IV.
39. Novartis AG (Villhauer EB): N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV. US-06110949 (2000).
40. Ferring BV (Jenkins PD, Jones DM, Szelke M): Inhibitors of DP-mediated processes, compositions and therapeutic methods thereof. US-06201132 (2001).
41. Probiodrug Gesellschaft fuer Arzneimittelforschung GMBH (Demuth H, Hoffmann T, Schlenzing D, Heiser U, Forstmeyer D): New effectors of dipeptidyl peptidase IV for topical use. WO-00114318 (2001).
42. Ferring BV (Evans DM, Pitt GRW): Inhibitors of dipeptidyl peptidase IV. WO-00181337 (2001).
43. Ferring BV (Evans DM, Pitt GRW): Inhibitors of dipeptidyl peptidase IV. WO-00181304 (2001).
44. Novartis AG (Damon R): Tetrahydroisoquinoline 3-carboxamide derivatives. US-06172081 (2001).
45. Welfide Corp (Kitajima H, Sakashita H, Akahoshi F, Hayashi Y): Proline derivatives and use thereof as drugs. WO-00214271 (2002).
46. Novartis AG (Villhauer E): Organic compounds. WO-00196295 (2001).
47. Guilford Pharmaceuticals Inc (Jackson P, Steiner J): Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors. WO-00134594 (2001).
48. Novo Nordisk A/S (Kansrup A, Lunsbeck JM, Christiansen LB): N-substituted 2-cyanopyroles and pyrrolines which are inhibitors of the enzyme DPP-IV. WO-00155105 (2001).
49. Bristol-Myers Squibb Co (Robl L, Sulsky RB, Augeri DJ, Magnin DR, Hamann LG, Betebenner DA): Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method. WO-00168603 (2001).
50. Novo Nordisk (Kansrup AB, Christiansen LB, Lunbeck JM, Sams CK, Kristiansen M): Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV. WO-00202560 (2002).
51. Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (Takeuchi T, Hamada M, Muraoka Y, Akiyama T, Abe M, Naganawa H, Takahashi Y): Physiologically active substance sulphostin, process for producing the same, and use thereof. US-06214340 (2001).
52. Probiodrug Gesellschaft fuer Arzneimittelforschung GmbH (Demuth H, Schmidt J, Hoffmann T, Glund K): Compounds of unstable DPIV-inhibitors. US-20010020006 (2001).
53. Ferring BV (Evans DM): Novel antidiabetic agents. WO-00140180 (2001).
54. Probiodrug Gesellschaft fuer Arzneimittelforschung GmbH (Demuth H, Rosche F, Schmidt J, Pauly R, McIntosh CHS, Pederson RA): Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals. US-06303661 (2001). First published claim for the use of DPP-IV inhibitors in the treatment of diabetes.
55. Novo Nordisk A/S (Carr RD): Inhibition of β-cell degeneration. WO-00162266 (2001). Claims the use of DPP-IV inhibitors in the prevention of diabetes.
56. Probiodrug Gesellschaft fuer Arzneimittelforschung GmbH (Demuth H, Glund K): Method for the improvement of islet signalling in diabetes mellitus and for its prevention. WO-00172290 (2001).
57. Novartis AG (Balkan B, Hughes TE, Holmes DG, Villhauer EB): Combinations comprising dipeptidylpeptidase-IV inhibitor. WO-00152825 (2001).
58. SmithKline Beecham plc (Arch JRS, Lenhard JM): Combination of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus. WO-00197808 (2001).
59. Probiodrug Gesellschaft fuer Arzneimittelforschung GmbH (Demuth H, Hoffmann T, Kuhn-Wache K, Rosche F): Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV. US-06319893 (2001).
60. Pospislik AJ, Demuth H, Glund K, Hoffmann M, Mcintosh CHS, Pederson RA: Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals. US-20020006899 (2002).